Revolution Medicines (NASDAQ:RVMD) Insider Alan Sandler Sells 6,309 Shares of Stock

Revolution Medicines, Inc. (NASDAQ:RVMD) insider Alan Sandler sold 6,309 shares of the business’s stock in a transaction that occurred on Tuesday, September 29th. The shares were sold at an average price of $202.14, for a total value of $1,275,301.26. Following the completion of the sale, the insider owned 52,559 shares in the company, valued at $10,624,276.26. The trade was a 10.72% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Revolution Medicines Stock Up 0.3%

NASDAQ:RVMD traded up $0.63 during trading hours on Thursday, reaching $205.89. 1,710,457 shares of the stock were exchanged, compared to its average volume of 2,893,928. The stock has a market cap of $44.13 billion, a PE ratio of -23.34 and a beta of 1.40. Revolution Medicines, Inc. has a twelve month low of $45.60 and a twelve month high of $224.31. The firm has a 50 day moving average of $202.11 and a 200 day moving average of $165.61. The company has a debt-to-equity ratio of 0.40, a current ratio of 11.38 and a quick ratio of 11.38.

Revolution Medicines (NASDAQ:RVMD) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($3.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.04) by ($1.02). During the same quarter in the prior year, the business posted ($1.31) EPS. On average, equities analysts expect that Revolution Medicines, Inc. will post -8.87 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on RVMD. Guggenheim lifted their price target on shares of Revolution Medicines from $240.00 to $275.00 and gave the company a “buy” rating in a research note on Friday, August 28th. TD Cowen upgraded shares of Revolution Medicines to a “strong-buy” rating in a research note on Monday, August 24th. UBS Group raised their price objective on Revolution Medicines from $220.00 to $265.00 and gave the company a “buy” rating in a report on Friday, August 28th. Brookline Capital Markets began coverage on Revolution Medicines in a research report on Monday. They issued a “buy” rating and a $318.00 target price on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Revolution Medicines in a report on Friday, July 17th. Two analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Revolution Medicines has an average rating of “Moderate Buy” and an average price target of $234.33.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Burkett Financial Services LLC bought a new stake in shares of Revolution Medicines in the 3rd quarter valued at about $27,000. Contravisory Investment Management Inc. bought a new position in Revolution Medicines during the second quarter worth about $32,000. Johnson Financial Group Inc. bought a new position in Revolution Medicines during the second quarter worth about $37,000. Silvant Capital Management LLC acquired a new position in Revolution Medicines during the second quarter worth approximately $41,000. Finally, Northwestern Mutual Wealth Management Co. acquired a new position in Revolution Medicines during the second quarter worth approximately $41,000. Institutional investors own 94.34% of the company’s stock.

About Revolution Medicines

Revolution Medicines, Inc is a clinical-stage biotechnology company focused on developing targeted therapies for patients with cancer. The company’s research centers on the RAS signaling pathway, a key driver of tumor growth that is altered in many cancers, including those involving KRAS mutations.

Its pipeline includes RAS(ON) inhibitors designed to target active RAS proteins and address a range of RAS-driven tumors. Key development programs include daraxonrasib (RMC-6236), a broad-spectrum RAS inhibitor, and zoldonrasib (RMC-9805), an investigational inhibitor aimed at KRAS G12D-mutated cancers.